Table 1 Characteristics between the zoledronate and control groups. Continuous variables were described as mean (SD)
Zoledronate group (n = 59) | Control group (n = 66) | p value | |
|---|---|---|---|
Age (years) | 76.2 (7.6) | 78.0 (7.1) | 0.182 |
Gender (cases) | 0.147 | ||
Male | 16 | 26 | |
Female | 43 | 40 | |
Body mass index (kg/m2) | 22.5 (3.3) | 21.5 (3.1) | 0.106 |
Bone mineral density (t-scores) | − 3.1 (1.2) | − 2.9 (1.3) | 0.637 |
Facture sites (cases) | 0.590 | ||
Right | 35 | 36 | |
Left | 24 | 30 | |
ASA (scores) | 2.3 (0.6) | 2.3 (0.7) | 0.682 |
Anesthesia (cases) | |||
General | 5 | 7 | 0.686 |
Spinal | 54 | 59 | |
Operative time (min) | 75.0 (17.1) | 73.0 (25.3) | 0.616 |
Femoral head (cases) | 0.391 | ||
Metal | 9 | 14 | |
Ceramic | 50 | 52 | |
Follow-up (years) | 4.5 (1.8) | 4.0 (1.6) | 0.122 |